Low urgency

Order: Francis Esteban Matos: Final Debarment

Detected July 23, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA issued a final debarment order against Francis Esteban Matos, permanently prohibiting him from providing services to any drug manufacturer. This does not directly change regulatory requirements for businesses but serves as a compliance reminder regarding debarment checks.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 23, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. All drug manufacturers (branded, generic, API, contract, compounding) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately, but no specific deadline; ongoing compliance obligation.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

A specific individual has been added to the FDA debarment list.

Who it affects

All drug manufacturers (branded, generic, API, contract, compounding)

What you must do

Verify that Francis Esteban Matos is not currently employed or contracted in any capacity related to drug manufacturing.

Deadline

Immediately, but no specific deadline; ongoing compliance obligation.

Source: https://www.federalregister.gov/public-inspection/2026-14989/order-francis-esteban-matos-final-debarment

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)